New research demonstrates that delivery of engineered therapeutic dendritic cells that target lymphoid sites of tolerance induction can compensate for failing tolerance in the patient.
Jun 11, 2014 1:00:47 PM / by Maria posted in immune system, type 1 diabetes, Basic Research
New research demonstrates that delivery of engineered therapeutic dendritic cells that target lymphoid sites of tolerance induction can compensate for failing tolerance in the patient.